Cue Biopharma, Inc.
CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$26.84
Price-11.71%
-$3.56
1Y
Price
Market Cap
$70.534m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-339.4%
EBITDA Margin-346.6%
Net Profit Margin-419.9%
Free Cash Flow Margin-339.4%
EBITDA Margin-346.6%
Net Profit Margin-419.9%
Free Cash Flow MarginRevenue
$32.731m
-23.5%
1y CAGR+128.9%
3y CAGR+73.7%
5y CAGREarnings
-$19.523m
+7.4%
1y CAGR+10.5%
3y CAGR+2.9%
5y CAGREPS
-$5.53
+36.1%
1y CAGR+32.3%
3y CAGR+22.8%
5y CAGRBook Value
$21.608m
$30.877m
Assets$9.269m
Liabilities$3.440m
DebtDebt to Assets
11.1%
-0.2x
Debt to EBITDAFree Cash Flow
-$24.605m
+18.1%
1y CAGR+10.6%
3y CAGR+6.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company